Further characterization of somatic alterations in SDH-deficient GISTs is critically needed to advance development of new kinase inhibitors and to identify whether patients would benefit from chemotherapy agents such as fibroblast growth factor receptor inhibitors.11 Furthermore, there is insufficient knowledge on bioavailability of TKIs for fit patients who have significant chronic kidney disease. Here, SDHB is linked to chronic kidney disease.